Apr. 6, 2014 8:57 AM ET
- The benefits of including CD34+ cells in AMR-001.
- The benefits of including CXCR4+ cells in AMR-001.
- A new study indicates equal efficacy of autologous and allogeneic cell therapy for CAD.
- If you are not long in NBS, a good time to buy will be after April 8, 2014; release date of April’s issue of JACC.
Disclaimer: Shawn Arshad is not certified to give financial advice. Although well researched, please do your own research prior to investing. Shawn is not responsible for any actions one makes based on the information he provides.
To read the rest of this article, please: click here.